Pharmena S.A. (PHR.WA)
PLN 4.0
(-3.15%)
PLN 4.0
(-3.15%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 114 Thousand PLN | -41.24% |
| 2022 | 194 Thousand PLN | -60.41% |
| 2021 | 490 Thousand PLN | 257.66% |
| 2020 | 137 Thousand PLN | -36.57% |
| 2019 | 216 Thousand PLN | 254.1% |
| 2018 | 61 Thousand PLN | 52.5% |
| 2017 | 40 Thousand PLN | -56.99% |
| 2016 | 93 Thousand PLN | 13.41% |
| 2015 | 82 Thousand PLN | 20.59% |
| 2014 | 68 Thousand PLN | 300.0% |
| 2013 | 17 Thousand PLN | 0.0% |
| 2012 | - PLN | 0.0% |
| 2011 | - PLN | 0.0% |
| 2010 | - PLN | 0.0% |
| 2009 | - PLN | 0.0% |
| 2008 | - PLN | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 101 Thousand PLN | 0.0% |
| 2024 Q2 | 88 Thousand PLN | 0.0% |
| 2023 Q2 | 50 Thousand PLN | -60.63% |
| 2023 Q1 | 127 Thousand PLN | -34.54% |
| 2023 Q4 | 114 Thousand PLN | -49.56% |
| 2023 Q3 | 226 Thousand PLN | 352.0% |
| 2023 FY | 114 Thousand PLN | -41.24% |
| 2022 Q3 | 283 Thousand PLN | -19.6% |
| 2022 Q1 | 4.09 Million PLN | 735.71% |
| 2022 FY | 194 Thousand PLN | -60.41% |
| 2022 Q4 | 194 Thousand PLN | -31.45% |
| 2022 Q2 | 352 Thousand PLN | -91.4% |
| 2021 Q2 | 90 Thousand PLN | -15.89% |
| 2021 Q4 | 490 Thousand PLN | -9.26% |
| 2021 FY | 490 Thousand PLN | 257.66% |
| 2021 Q1 | 107 Thousand PLN | -21.9% |
| 2021 Q3 | 540 Thousand PLN | 500.0% |
| 2020 Q3 | 159 Thousand PLN | -34.57% |
| 2020 Q4 | 137 Thousand PLN | -13.84% |
| 2020 Q2 | 243 Thousand PLN | -27.25% |
| 2020 Q1 | 334 Thousand PLN | 54.63% |
| 2020 FY | 137 Thousand PLN | -36.57% |
| 2019 Q3 | 291 Thousand PLN | -19.17% |
| 2019 Q1 | 385 Thousand PLN | 531.15% |
| 2019 Q4 | 216 Thousand PLN | -25.77% |
| 2019 FY | 216 Thousand PLN | 254.1% |
| 2019 Q2 | 360 Thousand PLN | -6.49% |
| 2018 Q2 | 23 Thousand PLN | 53.33% |
| 2018 FY | 61 Thousand PLN | 52.5% |
| 2018 Q4 | 61 Thousand PLN | 306.67% |
| 2018 Q3 | 15 Thousand PLN | -34.78% |
| 2018 Q1 | 15 Thousand PLN | -62.5% |
| 2017 Q4 | 40 Thousand PLN | -20.0% |
| 2017 Q3 | 50 Thousand PLN | -15.25% |
| 2017 Q1 | 71 Thousand PLN | -23.66% |
| 2017 FY | 40 Thousand PLN | -56.99% |
| 2017 Q2 | 59 Thousand PLN | -16.9% |
| 2016 Q1 | 67 Thousand PLN | -18.29% |
| 2016 Q2 | 51 Thousand PLN | -23.88% |
| 2016 Q4 | 93 Thousand PLN | 165.71% |
| 2016 FY | 93 Thousand PLN | 13.41% |
| 2016 Q3 | 35 Thousand PLN | -31.37% |
| 2015 Q2 | 114 Thousand PLN | 86.89% |
| 2015 Q1 | 61 Thousand PLN | -10.29% |
| 2015 FY | 82 Thousand PLN | 20.59% |
| 2015 Q4 | 82 Thousand PLN | -18.0% |
| 2015 Q3 | 100 Thousand PLN | -12.28% |
| 2014 Q2 | 93 Thousand PLN | 564.29% |
| 2014 FY | 68 Thousand PLN | 300.0% |
| 2014 Q4 | 68 Thousand PLN | -18.07% |
| 2014 Q3 | 83 Thousand PLN | -10.75% |
| 2014 Q1 | 14 Thousand PLN | -17.65% |
| 2013 Q1 | - PLN | -100.0% |
| 2013 FY | 17 Thousand PLN | 0.0% |
| 2013 Q3 | 21 Thousand PLN | 0.0% |
| 2013 Q4 | 17 Thousand PLN | -19.05% |
| 2012 FY | - PLN | 0.0% |
| 2012 Q4 | 40 Thousand PLN | 0.0% |
| 2011 FY | - PLN | 0.0% |
| 2010 FY | - PLN | 0.0% |
| 2009 FY | - PLN | 0.0% |
| 2008 FY | - PLN | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bioceltix S.A. | 76.33 Thousand PLN | -49.346% |
| BIOTON S.A. | 12.67 Million PLN | 99.101% |
| Captor Therapeutics Spolka Akcyjna | 1.24 Million PLN | 90.858% |
| Mabion S.A. | 2.94 Million PLN | 96.133% |
| Molecure S.A. | 4.97 Million PLN | 97.709% |
| NanoGroup S.A. | - PLN | -Infinity% |
| Poltreg S.A. | 7.8 Million PLN | 98.539% |
| Pure Biologics Spólka Akcyjna | 12.85 Million PLN | 99.113% |
| Ryvu Therapeutics S.A. | 365 Thousand PLN | 68.767% |
| Synthaverse S.A. | 61.2 Million PLN | 99.814% |
| Urteste S.A. | 312 Thousand PLN | 63.462% |